BioSpace News Archive

Keros Therapeutics, Inc. announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 28th Annual Congress of the European Hematology Association, to be held both virtually and in person from June 8 through 15, 2023.

ALX Oncology Holdings Inc. reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights.

Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced results for the quarter ended March 31, 2023.

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Ventyx Biosciences, Inc. announced financial results for the first quarter ended March 31, 2023, and highlighted recent pipeline and business progress.

Adverum Biotechnologies, Inc. reported financial results for the first quarter ended March 31, 2023 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec for the treatment of wet age-related macular degeneration.

Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments.

Mustang Bio, Inc. announced that Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, will be presented at the European Hematology Association Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma taking place June 13-17, 2023, in Lugano, Switzerland.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced financial results for the first quarter ended March 31, 2023.

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.